Drug Abuse And US Presidential Politics: Surprising Bipartisan Agreement
Executive Summary
Donald Trump has a knack from making headlines, and produced a doozy when he called for drug tests of Hillary Clinton before the next Presidential debate; beneath the hoopla, however, was an important point of substance: the two campaigns actually agree that advancing addiction treatment is a high priority for federal action.
You may also be interested in...
Opioids: Senate Wants Mandatory Prescriber Training; Can FDA Make It Work?
Appropriations bill report includes language stating that it is 'imperative' the agency take all steps necessary to require opioid prescriber training.
Opana Safety Review Will Set Tone For Opioid Regulation Under Trump
FDA’s 2017 advisory committee calendar is extremely light, but the one product focused review on the schedule should be a doozy: a two-day look at safety issues with Endo’s Opana ER as well as generic versions of oxymorphone. The topic is likely to resonate with the Trump Administration and especially Vice President Pence.
Naloxone Efficacy Standard Changes Could Impact Amphastar's Pending NDA
FDA is reviewing Amphastar’s application for a new intranasal formulation at the same time it is reconsidering minimum pharmacokinetic standards for the opioid overdose reversal agent.